Tammy Meyers to Anti-HIV Agents
This is a "connection" page, showing publications Tammy Meyers has written about Anti-HIV Agents.
Connection Strength
1,996
-
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019 11 15; 33(14):2197-2203.
Score: 0,369
-
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. AIDS. 2013 Mar 13; 27(5):781-5.
Score: 0,232
-
Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. Psychol Health Med. 2012; 17(5):599-610.
Score: 0,215
-
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011 Nov; 30(11):974-9.
Score: 0,211
-
Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS. 2010 Jun 01; 24(9):1341-9.
Score: 0,191
-
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):201-204.
Score: 0,101
-
Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries. AIDS. 2015 Jan 02; 29(1):101-9.
Score: 0,066
-
Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2012 Oct 01; 61(2):235-42.
Score: 0,056
-
Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996-2011: light at the end of the tunnel? J Acquir Immune Defic Syndr. 2012 Aug 15; 60(5):503-10.
Score: 0,056
-
Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
Score: 0,056
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,054
-
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012 Apr; 68(4):339-47.
Score: 0,053
-
Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
Score: 0,050
-
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
Score: 0,050
-
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
Score: 0,049
-
Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):613-9.
Score: 0,048
-
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):439-43.
Score: 0,044
-
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
Score: 0,044
-
High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):133-6.
Score: 0,039
-
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1510-20.
Score: 0,012